Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MB-106 by Mustang Bio for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
MB-106 by Mustang Bio for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
MB-106 by Mustang Bio for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to...
MB-106 by Mustang Bio for Marginal Zone B-cell Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...
MB-106 by Mustang Bio for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According...
MB-106 by Mustang Bio for Follicular Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
MB-106 by Mustang Bio for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
MB-108 by Mustang Bio for Recurrent Malignant Glioma: Likelihood of Approval
MB-108 is under clinical development by Mustang Bio and currently in Phase I for Recurrent Malignant Glioma. According to GlobalData,...
MB-106 by Mustang Bio for Mantle Cell Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
MB-106 by Mustang Bio for Secondary CNS Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Secondary CNS Lymphoma. According to GlobalData,...
MB-106 by Mustang Bio for Primary CNS Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Primary CNS Lymphoma. According to GlobalData,...
MB-106 by Mustang Bio for Marginal Zone B-cell Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Marginal Zone B-cell Lymphoma. According to...
MB-106 by Mustang Bio for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According...
MB-106 by Mustang Bio for Follicular Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...
MB-106 by Mustang Bio for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
MB-101 by Mustang Bio for Glioblastoma Multiforme (GBM): Likelihood of Approval
MB-101 is under clinical development by Mustang Bio and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...
MB-106 by Mustang Bio for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...
MB-106 by Mustang Bio for Burkitt Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase...
MB-105 by Mustang Bio for Pancreatic Cancer: Likelihood of Approval
MB-105 is under clinical development by Mustang Bio and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
MB-106 by Mustang Bio for Mantle Cell Lymphoma: Likelihood of Approval
MB-106 is under clinical development by Mustang Bio and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...